{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:52:01Z","timestamp":1793040721834,"version":"4.5.0"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Ixchelsis Ltd, UK"},{"name":"Ixchelsis"},{"name":"Ixchelsis Ltd"}],"content-domain":{"domain":["jsm.jsexmed.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Cligosiban is an orally administered, centrally penetrant oxytocin receptor antagonist being developed to treat premature ejaculation (PE).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>To determine the efficacy of 3 dose levels of cligosiban caplets to prolong intravaginal ejaculation latency time (IELT) and improve patient-reported outcomes in men with lifelong PE.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients recorded details of at least 4 sexual intercourse events during a 4-week run-in period, after which they underwent baseline assessments. Patients were eligible for the study if their stopwatch-assessed IELT was \u22641 minute in \u226575% of intercourse attempts and if they met other diagnostic criteria for lifelong PE. Eligible patients (target 220 evaluable) were randomized to double-blind cligosiban 400, 800, or 1200 mg or matching placebo caplets (to be taken 1 to 6 hours prior to sexual activity). Assessments were conducted at 2, 4, and 8 weeks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measure<\/jats:title>\n                  <jats:p>Efficacy measures were comprised of IELT, self-rating of ejaculation control and ejaculation-related distress (recorded in an electronic diary after each intercourse attempt), premature ejaculation profile, Patient\u2019s Global Impression of Severity, and the Clinical Global Impression of Change.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>There were no clinically or statistically significant differences between cligosiban (at any dose level) and placebo for the primary endpoint (change in geometric IELT) or any of the secondary endpoints. Cligosiban was well tolerated with a side-effect profile similar to placebo.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Implications<\/jats:title>\n                  <jats:p>This Phase IIb study failed to demonstrate the potential for cligosiban, an oxytocin antagonist, to successfully treat symptoms of severe lifelong PE at doses up to 1200 mg.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Strengths and Limitations<\/jats:title>\n                  <jats:p>This was a Phase IIb, randomized, double-blind, placebo-controlled study that was adequately powered but failed to detect a clinically meaningful or statistical difference in change in IELT between cligosiban at 3 dose levels and placebo. This is in contrast to a similarly designed proof-of-concept study where cligosiban was flexibly dosed at doses up to 800 mg and did demonstrate clinically meaningful and statistically significant changes in efficacy parameters. The reasons for this disparity are not known.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Cligosiban was well tolerated but failed to demonstrate efficacy for the treatment of men with lifelong PE at doses up to 1200 mg.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1016\/j.jsxm.2019.05.015","type":"journal-article","created":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T23:12:01Z","timestamp":1564009921000},"page":"1188-1198","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["The Oxytocin Antagonist Cligosiban Fails to Prolong Intravaginal Ejaculatory Latency in Men with Lifelong Premature Ejaculation: Results of a Randomized, Double-Blind, Placebo-Controlled Phase IIb trial (PEDRIX)"],"prefix":"10.1093","volume":"16","author":[{"given":"Stanley","family":"Althof","sequence":"first","affiliation":[{"name":"Case Western Reserve University Medical School and Center for Marital and Sexual Health of South Florida , West Palm Beach, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian H.","family":"Osterloh","sequence":"additional","affiliation":[{"name":"Ixchelsis Ltd , Sandwich \u00a0 UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary J.","family":"Muirhead","sequence":"additional","affiliation":[{"name":"Ixchelsis Ltd , Sandwich \u00a0 UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"George","sequence":"additional","affiliation":[{"name":"Therapy Research Services Ltd , Headcorn \u00a0 UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"PEDRIX Multi-Centre Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,8,1]]},"reference":[{"key":"2023012309452410500_bib1","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1111\/j.1743-6109.2008.00825.x","article-title":"Impact of premature ejaculation: the psychological, quality of life, and sexual relationship consequences","volume":"5","author":"Rosen","year":"2008","journal-title":"J Sex Med"},{"key":"2023012309452410500_bib2","article-title":"Priligy 30 mg and 60 mg film-coated tablets","author":"Datapharm"},{"key":"2023012309452410500_bib3","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.jsxm.2018.09.006","article-title":"Pharmacokinetics, safety and tolerability of single oral doses of a novel oxytocin receptor antagonist cligosiban in development for premature ejaculation: three randomized clinical trials in healthy subjects","volume":"15","author":"Osterloh","year":"2018","journal-title":"J Sex Med"},{"key":"2023012309452410500_bib4","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.111.004952","article-title":"Pharmacology for the treatment of premature ejaculation","volume":"64","author":"Giuliano","year":"2012","journal-title":"Pharmacol Rev"},{"key":"2023012309452410500_bib5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/0018-506X(85)90002-9","article-title":"Oxytocin improves male copulatory performance in rats","volume":"19","author":"Arletti","year":"1985","journal-title":"Horm Behav"},{"key":"2023012309452410500_bib6","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0091-3057(89)90433-4","article-title":"Apomorphine stimulation of male copulatory behavior is prevented by the oxytocin antagonist d(CH2)5 Tyr(Me)-Orn8-vasotocin in rats","volume":"33","author":"Argiolas","year":"1989","journal-title":"Pharmacol Biochem Behav"},{"key":"2023012309452410500_bib7","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/bjp.2008.176","article-title":"Brain oxytocin receptors mediate ejaculation elicited by 7-hydroxy-2-(di-N-propylamino) tetralin (7-OH-DPAT) in anaesthetized rats","volume":"154","author":"Clement","year":"2008","journal-title":"Br J Pharmacol"},{"key":"2023012309452410500_bib8","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1111\/jsm.12272","article-title":"Safety and efficacy of epelsiban in the treatment of men with premature ejaculation: a randomized, double-blind, placebo-controlled, fixed-dose study","volume":"10","author":"Shinghal","year":"2013","journal-title":"J Sex Med"},{"key":"2023012309452410500_bib9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jsxm.2018.11.012","article-title":"Pharmacokinetics, safety and tolerability of multiple doses of the novel oxytocin receptor antagonist cligosiban in development for premature ejaculation: two randomized clinical trials in healthy subjects","volume":"16","author":"Muirhead","year":"2019","journal-title":"J Sex Med"},{"key":"2023012309452410500_bib10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsxm.2019.05.015","article-title":"The oxytocin antagonist cligosiban prolongs intravaginal ejaculatory latency and improves patient reported outcomes in men with lifelong premature ejaculation: results of a randomized, double-blind, placebo-controlled proof-of-concept trial (PEPIX)","author":"McMahon","year":"2019","journal-title":"J Sex Med"},{"key":"2023012309452410500_bib11","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1111\/jsm.12524","article-title":"An evidence-based unified definition of lifelong and acquired premature ejaculation: report of the second International Society for Sexual Medicine Ad Hoc Committee for the Definition of Premature Ejaculation","volume":"11","author":"Serefoglu","year":"2014","journal-title":"J Sex Med"},{"key":"2023012309452410500_bib12","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1464-410X.2008.08041.x","article-title":"The Premature Ejaculation Profile: validation of self-reported outcome measures for research and practice","volume":"103","author":"Patrick","year":"2009","journal-title":"BJU Int"},{"key":"2023012309452410500_bib13","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1471-2490-12-30","article-title":"Construct validation of patient global impression of severity (PGI-S) and improvement (PGI-I) questionnaires in the treatment of men with lower urinary tract symptoms secondary to benign prostatic hyperplasia","volume":"12","author":"Viktrup","year":"2012","journal-title":"BMC Urol"},{"key":"2023012309452410500_bib14","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0090-4295(97)00238-0","article-title":"The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction","volume":"49","author":"Rosen","year":"1997","journal-title":"Urology"},{"key":"2023012309452410500_bib15","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","journal-title":"J Gen Intern Med"},{"key":"2023012309452410500_bib16","article-title":"Columbia-Suicide Severity Rating Scale (C-SSRS): since last visit","author":"Posner"},{"key":"2023012309452410500_bib17","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1111\/j.1743-6109.2010.01793.x","article-title":"Validity of the patient-reported Clinical Global Impression of Change as a measure of treatment response in men with premature ejaculation","volume":"7","author":"Althof","year":"2010","journal-title":"J Sex Med"},{"key":"2023012309452410500_bib18","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.eururo.2009.01.025","article-title":"Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries","volume":"55","author":"Buvat","year":"2009","journal-title":"Eur Urol"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S174360951931224X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S174360951931224X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/16\/8\/1188\/48588981\/jsm_16_8_1188.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/16\/8\/1188\/48588981\/jsm_16_8_1188.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T10:22:24Z","timestamp":1674469344000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/16\/8\/1188\/6980596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,1]]},"references-count":18,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,8,1]]},"published-print":{"date-parts":[[2019,8,1]]}},"URL":"https:\/\/doi.org\/10.1016\/j.jsxm.2019.05.015","relation":{},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2019,8]]},"published":{"date-parts":[[2019,8,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Oxytocin Antagonist Cligosiban Fails to Prolong Intravaginal Ejaculatory Latency in Men with Lifelong Premature Ejaculation: Results of a Randomized, Double-Blind, Placebo-Controlled Phase IIb trial (PEDRIX)","name":"articletitle","label":"Article Title"},{"value":"The Journal of Sexual Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsxm.2019.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}